Protein expression, gene amplification, epidermal growth factor receptor mutations and lung carcinoma

Milana Panjković; Živka Eri; Aleksandra Lovrenski; Slavica Knežević-Ušaj; Tatjana Ivković-Kapicl

doi:10.2298/2806

Milana Panjković Institute for Lung Diseases of Vojvodina, Sremska Kamenica, Serbia
Živka Eri Institute for Lung Diseases of Vojvodina, Sremska Kamenica, Serbia
Aleksandra Lovrenski Institute for Lung Diseases of Vojvodina, Sremska Kamenica, Serbia
Slavica Knežević-Ušaj Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
Tatjana Ivković-Kapicl Oncology Institute of Vojvodina, Sremska Kamenica, Serbia

DOI: https://doi.org/10.2298/2806

Keywords: lung neoplasms, carcinoma, non-small-cell lung, gene amplification, gene expression, mutation, receptor, epidermal growth factor,

Author Biographies

Milana Panjković, Institute for Lung Diseases of Vojvodina, Sremska Kamenica, Serbia

Department for Pathology, Assistant Professor

Živka Eri, Institute for Lung Diseases of Vojvodina, Sremska Kamenica, Serbia

Department of Pathology, Professor

Aleksandra Lovrenski, Institute for Lung Diseases of Vojvodina, Sremska Kamenica, Serbia

Department of Pathology, Teaching Assistant

Slavica Knežević-Ušaj, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia

Department of Pathology, Professor

Tatjana Ivković-Kapicl, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia

Department of Pathology, Assistant Professor

References

Wenzlaff AS, Cote ML, Bock CH, Land SJ, Santer SK, Schwartz DR, et al. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 2005; 26(12): 2207−212.

Cox G, Jones JL, Byrne OK. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000; 6(6): 2349−55.

Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Immu-nohistochemical evidence of autocrine growth factors in ade-nocarcinoma of the human lung. Cancer Res 1990; 50(21): 7077−80.

di Carlo A, Mariano A, Macchia PE, Cecere C, Ferrante G, Macchia V. Epidermal growth factor receptor and lipid membrane components in human lung cancers. J Endocrinol Invest 1993; 16(2): 99−107.

Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987; 55(5): 513−6.

Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993; 13(4): 1133−7.

Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor in-hibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 2006; 1(1): 19.

Hirsh FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremnes RM, et al. Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis. J Clin Oncol 2003; 21(20): 3789−807.

Đačić S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C, et al. Significance of EGFR protein expression and gene am-plification in non-small cell lung carcinoma. Am J Clin Pathol 2006; 125(6): 860−5.

Tanner M, Gancberg D, Di LA, Larsimont D, Rouas G, Piccart MJ, Isola J. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000; 157(5): 1467−72.

Gallegos RM, Floor K, Vos W, Grünberg K, Meijer GA, Rodriguez JA, et al. Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization. Histopathology 2007; 51(5): 631−7.

Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridiza-tion. Clin Cancer Res 2004; 10(14): 4793−8.

Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 2002; 15(6): 657−65.

Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and ad-diction to EGFR: the Achilles 'heal' of lung cancers. Trends Mol Med 2004; 10(10): 481−6.

Miyamae Y, Shimizu K, Mitani Y, Araki T, Kawai Y, Baba M, et al. Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue. J Mol Diagn 2010; 12(2): 257−64.

Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, Ito S, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006; 12(1): 43−8.

Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos MG. Replacing PCR with COLD-PCR enriches variant DNA se-quences and redefines the sensitivity of genetic testing. Nat Med 2008; 14(5): 579−84.

Endo K, Konishi A, Sasaki H, Takada M, Tanaka H, Okumura M, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 2005; 50(3): 375−84.

Zhou Q, Zhang X, Chen Z, Yin X, Yang J, Xu C, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin On-col 2011; 29(24): 3316−21.

Azuma K, Okamoto I, Kawahara A, Taira T, Nakashima K, Hattori S, et al. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progres-sion-free survival after gefitinib treatment. J Thorac Oncol 2012; 7(1): 122−7.

Angulo B, Conde E, Suárez-Gauthier A, Plaza C, Martínez R, Re-dondo P, et al. A Comparison of EGFR Mutation Testing Me-thods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry. PLoS ONE 2012; 7(8): e43842.

Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65(5): 1642−6.

Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, et al. Polymorphism, Mutations and Amplification of the EGFR Gene in Non- Small Cell Lung Cancers. PloS Med 2007; 4(4): 715−27.

Sasaki H, Shimizu S, Endo K, Takada M, Kawahara M, Tanaka H, et al. EGFR and erbB2 mutation status in Japanese lung can-cer patients. Int J Cancer 2006; 118(1): 180−4.

Mok TS, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarci-noma. N Engl J Med 2009; 361(10): 947−57.

Sholl LM, Yeap BY, Iafrate JA, Holmes-Tisch AJ, Chou Y, Wu M, et al. Lung adenocarcinoma with EGFR amplification has dis-tinct clinicopathologic and molecular features in never-smokers. Cancer Res 2009; 69(21): 8341−8

Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11(4): 689−708.

Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, et al. Ran-domized, Placebo-Controlled, Phase II Study of Sequential Er-lotinib and Chemotherapy As First-Line Treatment for Ad-vanced Non-Small-Cell Lung Cancer. J Clin Oncol 2009; 27(30): 5080−7.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129−39.

Tsao MS, Sakurada A, Cutz JC. Erlotinib in Lung Cancer - Mo-lecular and Clinical Predictors of Outcome. N Engl J Med 2005; 353(2): 134−44.

Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005; 11(3): 1167−73.

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36): 13306−11.

Rosell R, Taron M, Reguart N, Isla D, Moran T. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 2006; 12(24): 7222−31.

Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadzi-uszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in ad-vanced non-small-cell lung cancer. J Clin Oncol 2006; 24(31): 5034−42.

Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Cerasoli GL, Bemis L, et al. . Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97(9): 643−55.

Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007; 14(3): 295−304.

Dediu M, Median D, Alexandru A, Vremes G, Gal C. Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib. J BUON 2007; 12(Suppl 1): S137−49.

Trevis WD, Brambilla B, Muller-Hermelink K, Harris CC. Pathology and genetics of tumors of the lung, pleura, thymus and heart. In: Trevis WD, Brambilla B, Muller-Hermelink K, Harris CC, editors. World Health Organization Classification of tumours. Lyon: IARC Press; 2004.

Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gu-merlock P, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridiza-tion associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest On-cology Group Study. J Clin Oncol 2005; 23(28): 6838−45.

West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006; 24(12): 1807−13.

Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26(9): 1472−8.

Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Di-agn 2007; 9(3): 320−6.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al.. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocar-cinoma. J Thorac Oncol 2011; 6(2): 244−85.

Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential impli-cations on pharmacologic treatment. J Clin Oncol 2005; 23(4): 857−65.

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epi-dermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97(5): 339−46.

Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tu-mor progression of EGFR-mutated lung cancer. Cancer Res 2008; 68(7): 2106−11.

Tang X, Varella-Garcia M, Xavier AC, Massarelli E, Ozburn N, Moran ,C et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res (Phila) 2008; 1(3): 192−200.

Panjković M. Prognostic significance of protein expression and gene amplification EGFR in patients with lung adenocarcino-ma [dissertation]. Novi Sad: School of Medicine; 2009.